Vaccines, Blood & Biologics
Resources for You
October 19, 2012 Approval Letter - Menomune-A/C/Y/W-135
Our STN: BL 103926/5162
Sanofi Pasteur, Inc.
Attention: Joseph H. Quinn
Swiftwater, PA 18370-0187
Dear Mr. Quinn:
We have approved your request to supplement your biologics license application (BLA) for Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, to include updated information in the Dosage and Administration section of the package insert regarding instruction on the method of vaccine reconstitution and administration and in the Indications and Usage section regarding serotype limitation (for consistency with other meningococcal vaccines); to include changes to the Description section to accurately reflect the mention of casein and casamino acid used during manufacture of the vaccine; and to add information regarding the appropriate age for use on the carton labels.
Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels. All final labeling should be submitted as Product Correspondence to this BLA at the time of use (prior to marketing) and include implementation information on FDA Form 356h.
In addition, please submit the final content of labeling (21 CFR 601.14) in SPL format via the FDA automated drug registration and listing system, (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Information on submitting SPL files using eLIST may be found in the guidance for industry titled, “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.
You may submit two draft copies of the proposed introductory advertising and promotional labeling with an FDA Form 2253 to the Center for Biologics Evaluation and Research, Advertising and Promotional Labeling Branch, HFM-602, 1401 Rockville Pike, Rockville, MD 20852-1448. You must submit copies of your final advertisement and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).
All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).
Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes these changes.
We will include the information contained in the above referenced supplement in your BLA file.
Wellington Sun, M.D.
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research